Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An Open-Label, Single-Dose, Phase 1/2 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Human Protein C (TAK-662) for the Treatment of Congenital Protein C Deficiency in Japanese Subjects Followed by an Extension Part

    Summary
    EudraCT number
    2022-003877-48
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    31 Oct 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    08 May 2025
    First version publication date
    08 May 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    TAK-662-1501
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04984889
    WHO universal trial number (UTN)
    U1111-1267-4412
    Other trial identifiers
    jRCT: jRCT2031210209
    Sponsors
    Sponsor organisation name
    Takeda
    Sponsor organisation address
    95 Hayden Avenue, Lexington, United States, MA 02421
    Public contact
    Study Director, Takeda, +1 877-825-3327, TrialDisclosures@takeda.com
    Scientific contact
    Study Director, Takeda, +1 877-825-3327, TrialDisclosures@takeda.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    10 Dec 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    31 Oct 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To measure the pharmacokinetic (PK) parameters of TAK-662 in asymptomatic participants with homozygous or double heterozygous congenital protein C deficiency in Japanese participants.
    Protection of trial subjects
    This study was conducted in accordance with International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) of GCP, the principles of the Declaration of Helsinki, as well as other applicable national and local ethical and legal requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    07 Sep 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Japan: 5
    Worldwide total number of subjects
    5
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    2
    Adolescents (12-17 years)
    1
    Adults (18-64 years)
    2
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    This study was conducted at 4 centers in Japan from 7 September 2021 to 31 October 2024. A total of 5 Japanese participants were enrolled in this 2-part study to receive TAK-662 in Pharmacokinetic (PK) part (Part 1) followed by 3 treatment options in the Extension part (Part 2) (on-demand, short-term, or long-term prophylaxis).

    Pre-assignment
    Screening details
    As per planned analysis, the Extension Part data was collected, analyzed and reported as per On-demand and Short-term Prophylaxis treatments and per dose level wise data was not collected in this study.

    Period 1
    Period 1 title
    PK Part: Up to 7 Days
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    PK Part: TAK-662
    Arm description
    Participants received a single 80 IU/kg dose of TAK-662, intravenous infusion on Day 1 in PK part.
    Arm type
    Experimental

    Investigational medicinal product name
    TAK-662
    Investigational medicinal product code
    Other name
    Protein C Concentrate
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    TAK-662 80 IU/kg administered as intravenous infusion.

    Number of subjects in period 1
    PK Part: TAK-662
    Started
    5
    Completed
    5
    Period 2
    Period 2 title
    Extension Part: Up to 35 Months
    Is this the baseline period?
    No
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Extension Part, On-demand Treatment (TAK-662)
    Arm description
    Participants with purpura fulminans (PF), coumarin-induced skin necrosis/warfarin-induced skin necrosis (CISN/WISN), and/or other acute thromboembolic episode received a single dose of TAK-662 (100-120 IU/kg), followed by three subsequent infusions, every 6 hours at a dose of 60-80 IU/kg, and followed by subsequent infusions (45-60 IU/kg) continued every 6 or 12 hours until resolution of all non-necrotic lesions and/or stabilization of thrombi. Treatment could be terminated when an acute episode improved.
    Arm type
    Experimental

    Investigational medicinal product name
    TAK-662
    Investigational medicinal product code
    Other name
    Protein C Concentrate
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    TAK-662 (100-120 IU/kg), followed by three subsequent infusions, every 6 hours at a dose of 60-80 IU/kg, and followed by subsequent infusions (45-60 IU/kg) continued every 6 or 12 hours until resolution of all non-necrotic lesions and/or stabilization of thrombi.

    Arm title
    Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Arm description
    Participants who required short-term prophylaxis of acute thrombotic episodes during surgery received TAK-662 at a dose of 100-120 IU/kg, intravenous infusion once daily, until anticoagulation therapy was successfully switched to TAK-662 prior to surgery. Fifteen minutes prior to surgery, a dose of 60-80 IU/kg was administered and continued once every 6 hours for the first 24 hours after surgery began. The frequency of infusions was reduced to 3 times daily between 24 and 48 hours, and twice daily after 48 hours at the same dose (45-60 IU/kg). Treatment with TAK-662 continued twice daily until anticoagulation therapy was initiated (if applicable) and the investigator determined that adequate level of the anticoagulation was achieved.
    Arm type
    Experimental

    Investigational medicinal product name
    TAK-662
    Investigational medicinal product code
    Other name
    Protein C Concentrate
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    TAK-662 at a dose of 100-120 IU/kg, intravenous infusion once daily, until anticoagulation therapy was successfully switched to TAK-662 prior to surgery. Fifteen minutes prior to surgery, a dose of 60-80 IU/kg was administered and continued once every 6 hours for the first 24 hours after surgery began. The frequency of infusions was reduced to 3 times daily between 24 and 48 hours, and twice daily after 48 hours at the same dose (45-60 IU/kg).

    Number of subjects in period 2
    Extension Part, On-demand Treatment (TAK-662) Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Started
    4
    1
    Completed
    4
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    PK Part: TAK-662
    Reporting group description
    Participants received a single 80 IU/kg dose of TAK-662, intravenous infusion on Day 1 in PK part.

    Reporting group values
    PK Part: TAK-662 Total
    Number of subjects
    5
    Age Categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    15.2 ( 8.87 ) -
    Gender categorical
    Units: Subjects
        Male
    4 4
        Female
    1 1
    Race/Ethnicity, Customized
    Units: Subjects
        Japanese
    5 5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    PK Part: TAK-662
    Reporting group description
    Participants received a single 80 IU/kg dose of TAK-662, intravenous infusion on Day 1 in PK part.
    Reporting group title
    Extension Part, On-demand Treatment (TAK-662)
    Reporting group description
    Participants with purpura fulminans (PF), coumarin-induced skin necrosis/warfarin-induced skin necrosis (CISN/WISN), and/or other acute thromboembolic episode received a single dose of TAK-662 (100-120 IU/kg), followed by three subsequent infusions, every 6 hours at a dose of 60-80 IU/kg, and followed by subsequent infusions (45-60 IU/kg) continued every 6 or 12 hours until resolution of all non-necrotic lesions and/or stabilization of thrombi. Treatment could be terminated when an acute episode improved.

    Reporting group title
    Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Reporting group description
    Participants who required short-term prophylaxis of acute thrombotic episodes during surgery received TAK-662 at a dose of 100-120 IU/kg, intravenous infusion once daily, until anticoagulation therapy was successfully switched to TAK-662 prior to surgery. Fifteen minutes prior to surgery, a dose of 60-80 IU/kg was administered and continued once every 6 hours for the first 24 hours after surgery began. The frequency of infusions was reduced to 3 times daily between 24 and 48 hours, and twice daily after 48 hours at the same dose (45-60 IU/kg). Treatment with TAK-662 continued twice daily until anticoagulation therapy was initiated (if applicable) and the investigator determined that adequate level of the anticoagulation was achieved.

    Subject analysis set title
    Extension Part, Long-term Prophylaxis Treatment (TAK-662)
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants who required long-term prophylaxis were planned to receive TAK-662 at a dose of 45-60 IU/kg, intravenous infusion, twice daily. The dose was to be adjusted by referring to the latest protein C activity at the investigator’s discretion. No participants received TAK-662 for long-term prophylaxis during the study.

    Primary: PK Part: Protein C Activity Level of TAK-662

    Close Top of page
    End point title
    PK Part: Protein C Activity Level of TAK-662 [1]
    End point description
    Protein C is a vitamin K-dependent plasma protein and is an important component of the coagulation system. Protein C activity level was measured by chromogenic assays. Protein C activity level of TAK-662 was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important protocol deviations (PDs)/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: international unit per milliliter(IU/ml)
    arithmetic mean (standard deviation)
        Pre-infusion
    0.000 ( 0.000 )
        0.5 hour
    1.746 ( 0.557 )
        1 hour
    1.616 ( 0.523 )
        2 hours
    1.458 ( 0.519 )
        4 hours
    1.168 ( 0.441 )
        8 hours
    0.844 ( 0.295 )
        12 hours
    0.632 ( 0.257 )
        24 hours
    0.304 ( 0.150 )
        36 hours
    0.148 ( 0.095 )
    No statistical analyses for this end point

    Primary: PK Part: Incremental Recovery (IR) of TAK-662

    Close Top of page
    End point title
    PK Part: Incremental Recovery (IR) of TAK-662 [2]
    End point description
    IR of TAK-662 was reported measured in terms of international unit per millilitre/ international unit per kilogram (IU/mL)/(IU/kg). The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: (IU/mL)/(IU/kg)
        arithmetic mean (standard deviation)
    0.02063 ( 0.006588 )
    No statistical analyses for this end point

    Primary: PK Part: Percentage of In-vivo Recovery (IVR) of TAK-662

    Close Top of page
    End point title
    PK Part: Percentage of In-vivo Recovery (IVR) of TAK-662 [3]
    End point description
    IVR corrected for plasma was determined using the formula: IVR (percentage [%])= (Maximum observed plasma concentration (Cmax) [IU/mL] – Concentration (C) pre-infusion [IU/mL]) * Plasma volume pre-infusion (PV) millilitre (mL)/ Dose (international unit [IU])*100 where Cmax was the observed Cmax value before baseline correction. IVR of TAK-662 measured in terms of percentage was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: percentage of IVR
        arithmetic mean (standard deviation)
    95.71 ( 31.22 )
    No statistical analyses for this end point

    Primary: PK Part: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of TAK-662

    Close Top of page
    End point title
    PK Part: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of TAK-662 [4]
    End point description
    AUClast of TAK-662 was reported measured in terms of international unit*hour per millilitre (IU*h/ml). The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: IU*h/ml
        geometric mean (geometric coefficient of variation)
    19.24 ( 47.0 )
    No statistical analyses for this end point

    Primary: PK Part: Terminal Phase Elimination Half-life (t1/2) of TAK-662

    Close Top of page
    End point title
    PK Part: Terminal Phase Elimination Half-life (t1/2) of TAK-662 [5]
    End point description
    t1/2 of TAK-662 was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: hour
        median (full range (min-max))
    11.6 (7.68 to 13.0)
    No statistical analyses for this end point

    Primary: PK Part: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of TAK-662

    Close Top of page
    End point title
    PK Part: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of TAK-662 [6]
    End point description
    AUC0-infinity of TAK-662 was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: IU*h/ml
        geometric mean (geometric coefficient of variation)
    21.88 ( 47.1 )
    No statistical analyses for this end point

    Primary: PK Part: Maximum Observed Plasma Concentration (Cmax) of TAK-662

    Close Top of page
    End point title
    PK Part: Maximum Observed Plasma Concentration (Cmax) of TAK-662 [7]
    End point description
    Cmax of TAK-662 was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: IU/ml
        geometric mean (geometric coefficient of variation)
    1.679 ( 31.7 )
    No statistical analyses for this end point

    Primary: PK Part: Time to Reach the Maximum Plasma Concentration (Tmax) of TAK-662

    Close Top of page
    End point title
    PK Part: Time to Reach the Maximum Plasma Concentration (Tmax) of TAK-662 [8]
    End point description
    Tmax of TAK-662 was reported. The PK population included all study participants who took at least 1 dose of TAK-662 and had enough number of quantifiable blood levels for TAK-662 collected post-dose without important PDs/violations or events thought to substantially affect the PK.
    End point type
    Primary
    End point timeframe
    Pre-infusion, 0.5, 1, 2, 4, 8, 12, 24, and 36 hours post-infusion
    Notes
    [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be analyzed for this endpoint.
    End point values
    PK Part: TAK-662
    Number of subjects analysed
    5
    Units: hour
        median (full range (min-max))
    0.53 (0.43 to 0.60)
    No statistical analyses for this end point

    Secondary: PK and Extension Parts: Number of Participants With Treatment-Related Adverse Experiences (AEs)

    Close Top of page
    End point title
    PK and Extension Parts: Number of Participants With Treatment-Related Adverse Experiences (AEs)
    End point description
    A treatment-related AE was defined as an adverse event that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug was not able to be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, might also be responsible. Number of participants with treatment-related AEs as assessed by the Investigator were reported. The safety population included all enrolled participants in the study who took at least 1 dose of TAK-662.
    End point type
    Secondary
    End point timeframe
    PK Part: From the start of study drug administration up to Day 7; Extension Part: From the first dose of study drug administration in the Extension Part up to 35 months
    End point values
    PK Part: TAK-662 Extension Part, On-demand Treatment (TAK-662) Extension Part, Short-term Prophylaxis Treatment (TAK-662) Extension Part, Long-term Prophylaxis Treatment (TAK-662)
    Number of subjects analysed
    5
    4
    1
    0 [9]
    Units: participants
    1
    0
    0
    Notes
    [9] - No participants received TAK-662 for long-term prophylaxis treatment.
    No statistical analyses for this end point

    Secondary: Extension Part: Number of Episode Rated as Effective, Effective With Complications, or Not Effective on Efficacy Rating Scale During On-Demand Treatment

    Close Top of page
    End point title
    Extension Part: Number of Episode Rated as Effective, Effective With Complications, or Not Effective on Efficacy Rating Scale During On-Demand Treatment
    End point description
    The treatment of episodes of PF, CISN/ WISN, and/or other vascular thromboembolic events were rated as “effective”, “effective with complications”, or “not effective” according to the efficacy rating scale, as judged by investigators on the basis of following criteria, Effective: stabilization and regression of skin lesions/stabilization of thrombi; Effective with complications: treatment was effective but caused an adverse drug reaction that interfered with the regimen (resulted in change of dose or frequency of dosing) or forcing discontinuation of treatment or introducing pathogenic viral infection; Not effective: all other cases. Efficacy Analysis Set in On-Demand Treatment included all participants who took at least 1 dose of TAK-662 on-demand in the extension part.
    End point type
    Secondary
    End point timeframe
    Extension Part: From the first dose of TAK-662 on-demand treatment in the Extension Part up to 35 months
    End point values
    Extension Part, On-demand Treatment (TAK-662)
    Number of subjects analysed
    4
    Units: treatment episodes
    number (not applicable)
        Effective
    19
        Effective With Complications
    0
        Not Effective
    0
    No statistical analyses for this end point

    Secondary: Extension Part: Percentage of Surgical Episodes During Short-Term Prophylaxis That is Free of Presentations of PF or Thromboembolic Complications

    Close Top of page
    End point title
    Extension Part: Percentage of Surgical Episodes During Short-Term Prophylaxis That is Free of Presentations of PF or Thromboembolic Complications
    End point description
    Percentage of surgical episodes for which TAK-662 was utilized as short-term prophylaxis that is free of presentations of PF or thromboembolic complications was reported. Efficacy Analysis Set in Short-term Prophylaxis included all participants who took at least 1 dose of TAK-662 during short-term prophylaxis in the extension part.
    End point type
    Secondary
    End point timeframe
    Extension Part: From the first dose of TAK-662 short-term prophylaxis treatment in the Extension Part up to 35 months
    End point values
    Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Number of subjects analysed
    1
    Units: percentage of episode
        number (confidence interval 95%)
    100.0 (2.50 to 100.00)
    No statistical analyses for this end point

    Secondary: Extension Part: Number of Episodes of PF and/or Thrombotic Episodes During Long-Term Prophylaxis

    Close Top of page
    End point title
    Extension Part: Number of Episodes of PF and/or Thrombotic Episodes During Long-Term Prophylaxis
    End point description
    Number of Episodes of PF and/or Thrombotic Episodes During Long-Term Prophylaxis was planned to be reported. Efficacy Analysis Set in long-term prophylaxis included all study participants who took at least 1 dose of TAK-662 during long-term prophylaxis in the extension part. The “Number of Participants Analysed” is zero because no participants received TAK-662 for long-term prophylaxis; therefore, no data was collected and reported.
    End point type
    Secondary
    End point timeframe
    Extension Part: From the first dose of TAK-662 long-term prophylaxis treatment in the Extension Part up to 35 months
    End point values
    Extension Part, Long-term Prophylaxis Treatment (TAK-662)
    Number of subjects analysed
    0 [10]
    Units: episode
        number (not applicable)
    Notes
    [10] - No participants received TAK-662 for long-term prophylaxis treatment.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    PK Part: From start of study drug administration up to Day 7; Extension part: From first dose of study drug administration in Extension Part up to up to 35 months
    Adverse event reporting additional description
    No participant received TAK-662 for long-term prophylaxis and therefore, no safety data could be collected and reported for ‘Extension Part, Long-term Prophylaxis treatment (TAK-662) arm.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.0
    Reporting groups
    Reporting group title
    PK Part: TAK-662
    Reporting group description
    Participants received a single 80 international unit per kilogram (IU/kg) dose of TAK-662, intravenous infusion on Day 1 in PK part.

    Reporting group title
    Extension Part, On-demand Treatment (TAK-662)
    Reporting group description
    Participants with purpura fulminans (PF), coumarin-induced skin necrosis/warfarin-induced skin necrosis (CISN/WISN), and/or other acute thromboembolic episode received a single dose of TAK-662 (100-120 IU/kg), followed by three subsequent infusions, every 6 hours at a dose of 60-80 IU/kg, and followed by subsequent infusions (45-60 IU/kg) continued every 6 or 12 hours until resolution of all non-necrotic lesions and/or stabilization of thrombi. Treatment could be terminated when an acute episode improved.

    Reporting group title
    Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Reporting group description
    Participants who required short-term prophylaxis of acute thrombotic episodes during surgery received TAK-662 at a dose of 100-120 IU/kg, intravenous infusion once daily, until anticoagulation therapy was successfully switched to TAK-662 prior to surgery. Fifteen minutes prior to surgery, a dose of 60-80 IU/kg was administered and continued once every 6 hours for the first 24 hours after surgery began. The frequency of infusions was reduced to 3 times daily between 24 and 48 hours, and twice daily after 48 hours at the same dose (45-60 IU/kg). Treatment with TAK-662 continued twice daily until anticoagulation therapy was initiated (if applicable) and the investigator determined that adequate level of the anticoagulation was achieved.

    Serious adverse events
    PK Part: TAK-662 Extension Part, On-demand Treatment (TAK-662) Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    PK Part: TAK-662 Extension Part, On-demand Treatment (TAK-662) Extension Part, Short-term Prophylaxis Treatment (TAK-662)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 5 (40.00%)
    3 / 4 (75.00%)
    0 / 1 (0.00%)
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    Skin and subcutaneous tissue disorders
    Decubitus ulcer
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    Purpura
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    Oral herpes
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    13 Apr 2021
    Protocol Amendment 1.0: •Regarding inclusion criteria 1 and 2, actions to be taken when consent was not able to be obtained from the participant were added. •The collection of AEs was changed by the follow-up on Day 7.
    02 Sep 2021
    Protocol Amendment 2.0: •The rationale, study design, objectives and endpoints, dosage regimen and dose adjustment, inclusion/exclusion criteria, assessments, blood sampling volume, acceptable concomitant treatment, and handling of SAE for the extension part were added. Justification: based on investigator's careful evaluation on participant's medical condition, on-demand therapy, short-term prophylaxis and/or long-term prophylaxis were allowed to be conducted as the extension part in the participants who had completed PK part. •The injection rate was added. Justification: to align the injection time with the current US package insert to assure participant's safety. •The handling of the vials was changed. Justification: in order to align with the pharmacy manual. •The instruction of self-injection was added. Justification: self-injection was allowed in the extension part. •Description of planned interim analysis was added in Section 9.2. Justification: to clarify the timing of the primary analysis because the extension part was added. •Section 9.7 was simplified including deletion of Table 4. Justification: to describe the detail of PK analyses in the CPAP. •Correction of inconsistencies within the Protocol Amendment 1.0.
    08 Sep 2022
    Protocol Amendment 3.0: •The description of "Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee" of statistical analysis in Section 1.1 and Section 9.2 was changed to use the safety and efficacy data of the extension part for the first interim analysis. •The supporting description on the procedure of on-demand treatment at home after the first infusion for the second and subsequent acute episode was added in the footnote (f) of Table 3 in Section 1.3 and in Section 8.1.2.3.1. •Editorial correction of the Protocol Amendment 2.0.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 17:47:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA